1
|
M’Kacher R, Colicchio B, Junker S, El Maalouf E, Heidingsfelder L, Plesch A, Dieterlen A, Jeandidier E, Carde P, Voisin P. High Resolution and Automatable Cytogenetic Biodosimetry Using In Situ Telomere and Centromere Hybridization for the Accurate Detection of DNA Damage: An Overview. Int J Mol Sci 2023; 24:ijms24065699. [PMID: 36982772 PMCID: PMC10054499 DOI: 10.3390/ijms24065699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 03/07/2023] [Accepted: 03/10/2023] [Indexed: 03/19/2023] Open
Abstract
In the event of a radiological or nuclear accident, or when physical dosimetry is not available, the scoring of radiation-induced chromosomal aberrations in lymphocytes constitutes an essential tool for the estimation of the absorbed dose of the exposed individual and for effective triage. Cytogenetic biodosimetry employs different cytogenetic assays including the scoring of dicentrics, micronuclei, and translocations as well as analyses of induced premature chromosome condensation to define the frequency of chromosome aberrations. However, inherent challenges using these techniques include the considerable time span from sampling to result, the sensitivity and specificity of the various techniques, and the requirement of highly skilled personnel. Thus, techniques that obviate these challenges are needed. The introduction of telomere and centromere (TC) staining have successfully met these challenges and, in addition, greatly improved the efficiency of cytogenetic biodosimetry through the development of automated approaches, thus reducing the need for specialized personnel. Here, we review the role of the various cytogenetic dosimeters and their recent improvements in the management of populations exposed to genotoxic agents such as ionizing radiation. Finally, we discuss the emerging potentials to exploit these techniques in a wider spectrum of medical and biological applications, e.g., in cancer biology to identify prognostic biomarkers for the optimal triage and treatment of patients.
Collapse
Affiliation(s)
- Radhia M’Kacher
- Cell Environment DNA Damage R&D, Genopole, 91000 Evry-Courcouronnes, France
- Correspondence: ; Tel.: +33-160878918
| | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 69093 Mulhouse, France
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, DK-8000 Aarhus, Denmark
| | - Elie El Maalouf
- Cell Environment DNA Damage R&D, Genopole, 91000 Evry-Courcouronnes, France
| | | | - Andreas Plesch
- MetaSystems GmbH, Robert-Bosch-Str. 6, D-68804 Altlussheim, Germany
| | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 69093 Mulhouse, France
| | - Eric Jeandidier
- Laboratoire de Génétique, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, 69093 Mulhouse, France
| | - Patrice Carde
- Department of Hematology, Institut Gustave Roussy, 94804 Villejuif, France
| | - Philippe Voisin
- Cell Environment DNA Damage R&D, Genopole, 91000 Evry-Courcouronnes, France
| |
Collapse
|
2
|
Barbier MT, Del Valle L. Co-Detection of EBV and Human Polyomavirus JCPyV in a Case of AIDS-Related Multifocal Primary Central Nervous System Diffuse Large B-Cell Lymphoma. Viruses 2023; 15:755. [PMID: 36992464 PMCID: PMC10059075 DOI: 10.3390/v15030755] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 03/09/2023] [Accepted: 03/10/2023] [Indexed: 03/17/2023] Open
Abstract
The human neurotropic Polyomavirus JCPyV is the widespread opportunistic causative pathogen of the fatal demyelinating disease progressive multifocal leukoencephalopathy; however, it has also been implicated in the oncogenesis of several types of cancers. It causes brain tumors when intracerebrally inoculated into rodents, and genomic sequences of different strains and expression of the viral protein large T-Antigen have been detected in a wide variety of glial brain tumors and CNS lymphomas. Here, we present a case of an AIDS-related multifocal primary CNS lymphoma in which JCPyV genomic sequences of the three regions of JCPyV and expression of T-Antigen were detected by PCR and immunohistochemistry, respectively. No capsid proteins were detected, ruling out active JCPyV replication. Sequencing of the control region revealed that Mad-4 was the strain of JCPyV present in tumor cells. In addition, expression of viral proteins LMP and EBNA-1 from another ubiquitous oncogenic virus, Epstein-Barr, was also detected in the same lymphocytic neoplastic cells, co-localizing with JCPyV T-Antigen, suggesting a potential collaboration between these two viruses in the process of malignant transformation of B-lymphocytes, which are the site of latency and reactivation for both viruses.
Collapse
Affiliation(s)
- Mallory T. Barbier
- Louisiana Cancer Research Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
| | - Luis Del Valle
- Louisiana Cancer Research Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
- Department of Pathology, Louisiana State University School of Medicine, New Orleans, LA 70112, USA
| |
Collapse
|
3
|
Li Z, Ma Z, Xue H, Shen R, Qin K, Zhang Y, Zheng X, Zhang G. Chromatin Separation Regulators Predict the Prognosis and Immune Microenvironment Estimation in Lung Adenocarcinoma. Front Genet 2022; 13:917150. [PMID: 35873497 PMCID: PMC9305311 DOI: 10.3389/fgene.2022.917150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Accepted: 05/23/2022] [Indexed: 11/24/2022] Open
Abstract
Background: Abnormal chromosome segregation is identified to be a common hallmark of cancer. However, the specific predictive value of it in lung adenocarcinoma (LUAD) is unclear. Method: The RNA sequencing and the clinical data of LUAD were acquired from The Cancer Genome Atlas (TACG) database, and the prognosis-related genes were identified. The Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) were carried out for functional enrichment analysis of the prognosis genes. The independent prognosis signature was determined to construct the nomogram Cox model. Unsupervised clustering analysis was performed to identify the distinguishing clusters in LUAD-samples based on the expression of chromosome segregation regulators (CSRs). The differentially expressed genes (DEGs) and the enriched biological processes and pathways between different clusters were identified. The immune environment estimation, including immune cell infiltration, HLA family genes, immune checkpoint genes, and tumor immune dysfunction and exclusion (TIDE), was assessed between the clusters. The potential small-molecular chemotherapeutics for the individual treatments were predicted via the connectivity map (CMap) database. Results: A total of 2,416 genes were determined as the prognosis-related genes in LUAD. Chromosome segregation is found to be the main bioprocess enriched by the prognostic genes. A total of 48 CSRs were found to be differentially expressed in LUAD samples and were correlated with the poor outcome in LUAD. Nine CSRs were identified as the independent prognostic signatures to construct the nomogram Cox model. The LUAD-samples were divided into two distinct clusters according to the expression of the 48 CSRs. Cell cycle and chromosome segregation regulated genes were enriched in cluster 1, while metabolism regulated genes were enriched in cluster 2. Patients in cluster 2 had a higher score of immune, stroma, and HLA family components, while those in cluster 1 had higher scores of TIDES and immune checkpoint genes. According to the hub genes highly expressed in cluster 1, 74 small-molecular chemotherapeutics were predicted to be effective for the patients at high risk. Conclusion: Our results indicate that the CSRs were correlated with the poor prognosis and the possible immunotherapy resistance in LUAD.
Collapse
Affiliation(s)
- Zhaoshui Li
- Qingdao Medical College, Qingdao University, Qingdao, China
- Cardiothoracic Surgery Department, Qingdao Hiser Hospital Affiliated to Qingdao University, Qingdao, China
| | - Zaiqi Ma
- Cardiothoracic Surgery Department, Qingdao Hiser Hospital Affiliated to Qingdao University, Qingdao, China
| | - Hong Xue
- Heart Center Department, Qingdao Hiser Hospital Affiliated to Qingdao University, Qingdao, China
| | - Ruxin Shen
- Qingdao Medical College, Qingdao University, Qingdao, China
| | - Kun Qin
- Qingdao Medical College, Qingdao University, Qingdao, China
| | - Yu Zhang
- Qingdao Medical College, Qingdao University, Qingdao, China
| | - Xin Zheng
- Cancer Center Department, Qingdao Hiser Hospital Affiliated to Qingdao University, Qingdao, China
- *Correspondence: Xin Zheng, ; Guodong Zhang,
| | - Guodong Zhang
- Thoracic Surgery Department, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, China
- *Correspondence: Xin Zheng, ; Guodong Zhang,
| |
Collapse
|
4
|
Soumboundou M, Dossou J, Kalaga Y, Nkengurutse I, Faye I, Guingani A, Gadji M, Yameogo KJ, Zongo H, Mbaye G, Dem A, Diarra M, Adjibade R, Djebou C, Junker S, Oudrhiri N, Hempel WM, Dieterlen A, Jeandidier E, Carde P, El Maalouf E, Colicchio B, Bennaceur-Griscelli A, Fenech M, Voisin P, Rodriguez-Lafrasse C, M'Kacher R. Is Response to Genotoxic Stress Similar in Populations of African and European Ancestry? A Study of Dose-Response After in vitro Irradiation. Front Genet 2021; 12:657999. [PMID: 34868192 PMCID: PMC8632650 DOI: 10.3389/fgene.2021.657999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2021] [Accepted: 05/13/2021] [Indexed: 11/17/2022] Open
Abstract
Background: Exposure to genotoxic stress such as radiation is an important public health issue affecting a large population. The necessity of analyzing cytogenetic effects of such exposure is related to the need to estimate the associated risk. Cytogenetic biological dosimetry is based on the relationship between the absorbed dose and the frequency of scored chromosomal aberrations. The influence of confounding factors on radiation response is a topical issue. The role of ethnicity is unclear. Here, we compared the dose-response curves obtained after irradiation of circulating lymphocytes from healthy donors of African and European ancestry. Materials and Methods: Blood samples from six Africans living in Africa, five Africans living in Europe, and five Caucasians living in Europe were exposed to various doses (0–4 Gy) of X-rays at a dose-rate of 0.1 Gy/min using an X-RAD320 irradiator. A validated cohort composed of 14 healthy Africans living in three African countries was included and blood samples were irradiated using the same protocols. Blood lymphocytes were cultured for 48 h and chromosomal aberrations scored during the first mitosis by telomere and centromere staining. The distribution of dicentric chromosomes was determined and the Kruskal-Wallis test was used to compare the dose-response curves of the two populations. Results: No spontaneous dicentric chromosomes were detected in African donors, thus establishing a very low background of unstable chromosomal aberrations relative to the European population. There was a significant difference in the dose response curves between native African and European donors. At 4 Gy, African donors showed a significantly lower frequency of dicentric chromosomes (p = 8.65 10–17), centric rings (p = 4.0310–14), and resulting double-strand-breaks (DSB) (p = 1.32 10–18) than European donors. In addition, a significant difference was found between African donors living in Europe and Africans living in Africa. Conclusion: This is the first study to demonstrate the important role of ethnic and environmental factors that may epigenetically influence the response to irradiation. It will be necessary to establish country-of-origen-specific dose response curves to practice precise and adequate biological dosimetry. This work opens new perspective for the comparison of treatments based on genotoxic agents, such as irradiation.
Collapse
Affiliation(s)
| | - Julien Dossou
- Département du Génie d'Imagerie Médicale et Radiobiologie, Cotonou, Benin
| | - Yossef Kalaga
- Centre Hospitalier Yalgado Radioprotection-Radiobiologie, Ouagadougou, Burkina Faso
| | | | | | - Albert Guingani
- Centre Hospitalier Yalgado Radioprotection-Radiobiologie, Ouagadougou, Burkina Faso
| | | | - Koudbi J Yameogo
- Centre Hospitalier Yalgado Radioprotection-Radiobiologie, Ouagadougou, Burkina Faso
| | - Henri Zongo
- Centre Hospitalier Yalgado Radioprotection-Radiobiologie, Ouagadougou, Burkina Faso
| | - Gora Mbaye
- Laboratoire Biophysique UFR-Santé, Dakar, Senegal
| | | | | | - Rached Adjibade
- Département du Génie d'Imagerie Médicale et Radiobiologie, Cotonou, Benin
| | - Catherine Djebou
- Département du Génie d'Imagerie Médicale et Radiobiologie, Cotonou, Benin
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, Aarhus, Denmark
| | - Noufissa Oudrhiri
- APHP-Service d'Hématologie - Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/Inserm UMR 935, Villejuif, France
| | | | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, Mulhouse, France
| | - Eric Jeandidier
- Service de Génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Mulhouse, France
| | - Patrice Carde
- Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, France
| | | | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, Mulhouse, France
| | - Annelise Bennaceur-Griscelli
- APHP-Service d'Hématologie - Oncohématologie Moléculaire et Cytogénétique Hôpital Paul Brousse Université Paris Saclay/Inserm UMR 935, Villejuif, France
| | - Michael Fenech
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia.,Genome Health Foundation, North Brighton, SA, Australia.,Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| | | | - Claire Rodriguez-Lafrasse
- Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, UMR CNRS5822/IN2P3, IPNL, PRISME, Oullins, France
| | | |
Collapse
|
5
|
Frias S. Genomic chaos in peripheral blood lymphocytes of hodgkins lymphoma patients 1 year after ABVD chemotherapy/radiotherapy. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2019; 60:387-388. [PMID: 30861193 DOI: 10.1002/em.22279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Accepted: 02/27/2019] [Indexed: 06/09/2023]
Affiliation(s)
- Sara Frias
- Laboratorio de Citogenética, INP, Insurgentes Sur 3700-C, 6o. piso, Cd. De Mexico, Mexico
| |
Collapse
|
6
|
M'kacher R, Junker S, Jeandidier E, Carde P. Letter to the editor of environmental and molecular mutagenesis: In regard to Ramos et al. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2019; 60:385-386. [PMID: 30851116 DOI: 10.1002/em.22282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Accepted: 02/27/2019] [Indexed: 06/09/2023]
Affiliation(s)
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, Aarhus, Denmark
| | - Eric Jeandidier
- Department of Genetic, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, Mulhouse, France
| | - Patrice Carde
- Department of Medicine, Gustave Roussy Cancer Campus, University Paris-Saclay, Villejuif, France
| |
Collapse
|
7
|
Frias S, Ramos S, Salas C, Molina B, Sánchez S, Rivera-Luna R. Nonclonal Chromosome Aberrations and Genome Chaos in Somatic and Germ Cells from Patients and Survivors of Hodgkin Lymphoma. Genes (Basel) 2019; 10:genes10010037. [PMID: 30634664 PMCID: PMC6357137 DOI: 10.3390/genes10010037] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2018] [Revised: 12/10/2018] [Accepted: 01/04/2019] [Indexed: 12/27/2022] Open
Abstract
Anticancer regimens for Hodgkin lymphoma (HL) patients include highly genotoxic drugs that have been very successful in killing tumor cells and providing a 90% disease-free survival at five years. However, some of these treatments do not have a specific cell target, damaging both cancerous and normal cells. Thus, HL survivors have a high risk of developing new primary cancers, both hematologic and solid tumors, which have been related to treatment. Several studies have shown that after treatment, HL patients and survivors present persistent chromosomal instability, including nonclonal chromosomal aberrations. The frequency and type of chromosomal abnormalities appear to depend on the type of therapy and the cell type examined. For example, MOPP chemotherapy affects hematopoietic and germ stem cells leading to long-term genotoxic effects and azoospermia, while ABVD chemotherapy affects transiently sperm cells, with most of the patients showing recovery of spermatogenesis. Both regimens have long-term effects in somatic cells, presenting nonclonal chromosomal aberrations and genomic chaos in a fraction of noncancerous cells. This is a source of karyotypic heterogeneity that could eventually generate a more stable population acquiring clonal chromosomal aberrations and leading towards the development of a new cancer.
Collapse
Affiliation(s)
- Sara Frias
- Laboratorio de Citogenética, Instituto Nacional de Pediatría, Cd. De Mexico, P.O. Box 04530, Mexico.
- Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de Mexico, Cd. De Mexico, P.O. Box 04510, Mexico.
| | - Sandra Ramos
- Laboratorio de Citogenética, Instituto Nacional de Pediatría, Cd. De Mexico, P.O. Box 04530, Mexico.
| | - Consuelo Salas
- Laboratorio de Genética y Cáncer, Instituto Nacional de Pediatría, Cd. De Mexico, P.O. Box 04530, Mexico.
| | - Bertha Molina
- Laboratorio de Citogenética, Instituto Nacional de Pediatría, Cd. De Mexico, P.O. Box 04530, Mexico.
| | - Silvia Sánchez
- Laboratorio de Citogenética, Instituto Nacional de Pediatría, Cd. De Mexico, P.O. Box 04530, Mexico.
| | - Roberto Rivera-Luna
- Subdirección de Hemato-Oncología, Instituto Nacional de Pediatría, Cd. De Mexico, P.O. Box 04530, Mexico.
| |
Collapse
|
8
|
M'kacher R, Frenzel M, Al Jawhari M, Junker S, Cuceu C, Morat L, Bauchet AL, Stimmer L, Lenain A, Dechamps N, Hempel WM, Pottier G, Heidingsfelder L, Laplagne E, Borie C, Oudrhiri N, Jouni D, Bennaceur-Griscelli A, Colicchio B, Dieterlen A, Girinsky T, Boisgard R, Bourhis J, Bosq J, Mehrling T, Jeandidier E, Carde P. Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies. Cancers (Basel) 2018; 10:cancers10110414. [PMID: 30384446 PMCID: PMC6265845 DOI: 10.3390/cancers10110414] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 10/25/2018] [Accepted: 10/26/2018] [Indexed: 01/16/2023] Open
Abstract
To identify the cells responsible for the initiation and maintenance of Hodgkin lymphoma (HL) cells, we have characterized a subpopulation of HL cells grown in vitro and in vivo with the aim of establishing a reliable and robust animal model for HL. To validate our model, we challenged the tumor cells in vivo by injecting the alkylating histone-deacetylase inhibitor, EDO-S101, a salvage regimen for HL patients, into xenografted mice. Methodology: Blood lymphocytes from 50 HL patients and seven HL cell lines were used. Immunohistochemistry, flow cytometry, and cytogenetics analyses were performed. The in vitro and in vivo effects of EDO-S101 were assessed. Results: We have successfully determined conditions for in vitro amplification and characterization of the HL L428-c subline, containing a higher proportion of CD30−/CD15− cells than the parental L428 cell line. This subline displayed excellent clonogenic potential and reliable reproducibility upon xenografting into immunodeficient NOD-SCID-gamma (−/−)(NSG) mice. Using cell sorting, we demonstrate that CD30−/CD15− subpopulations can gain the phenotype of the L428-c cell line in vitro. Moreover, the human cells recovered from the seventh week after injection of L428-c cells into NSG mice were small cells characterized by a high frequency of CD30−/CD15− cells. Cytogenetic analysis demonstrated that they were diploid and showed high telomere instability and telomerase activity. Accordingly, chromosomal instability emerged, as shown by the formation of dicentric chromosomes, ring chromosomes, and breakage/fusion/bridge cycles. Similarly, high telomerase activity and telomere instability were detected in circulating lymphocytes from HL patients. The beneficial effect of the histone-deacetylase inhibitor EDO-S101 as an anti-tumor drug validated our animal model. Conclusion: Our HL animal model requires only 103 cells and is characterized by a high survival/toxicity ratio and high reproducibility. Moreover, the cells that engraft in mice are characterized by a high frequency of small CD30−/CD15− cells exhibiting high telomerase activity and telomere dysfunction.
Collapse
Affiliation(s)
- Radhia M'kacher
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
- Cell Environment, Oncology Section, 75020 Paris, France.
| | - Monika Frenzel
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Mustafa Al Jawhari
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, DK-8000 Aarhus C, Denmark.
| | - Corina Cuceu
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Luc Morat
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Anne-Laure Bauchet
- Platform for Experimental Pathology PathEX/CRC MIRCen/CEA-INSERM, University Paris-Saclay, 92265 Fontenay aux Rroses, France.
| | - Lev Stimmer
- Platform for Experimental Pathology PathEX/CRC MIRCen/CEA-INSERM, University Paris-Saclay, 92265 Fontenay aux Rroses, France.
| | - Aude Lenain
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Nathalie Dechamps
- Platform for Cell Sorting, CEA, iRCM, 92265 Fontenay aux Roses, France.
| | - William M Hempel
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Geraldine Pottier
- Laboratoire d'Imagerie Moléculaire Expérimentale Groupe d'Imagerie du Petit Animal CEA/DSV/I2BM/SHFJ/U1023, University Paris-Saclay, 91400 Orsay, France.
| | | | | | - Claire Borie
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | - Noufissa Oudrhiri
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | - Dima Jouni
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | | | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Theodore Girinsky
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| | - Raphael Boisgard
- Laboratoire d'Imagerie Moléculaire Expérimentale Groupe d'Imagerie du Petit Animal CEA/DSV/I2BM/SHFJ/U1023, University Paris-Saclay, 91400 Orsay, France.
| | - Jean Bourhis
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| | - Jacques Bosq
- Departement of Anapathology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Vilejuif, France.
| | | | - Eric Jeandidier
- Department of Genetic, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, 68093 Mulhouse, France.
| | - Patrice Carde
- Department of Medicine, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| |
Collapse
|
9
|
Independent Mechanisms Lead to Genomic Instability in Hodgkin Lymphoma: Microsatellite or Chromosomal Instability †. Cancers (Basel) 2018; 10:cancers10070233. [PMID: 30011886 PMCID: PMC6071189 DOI: 10.3390/cancers10070233] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2018] [Revised: 06/29/2018] [Accepted: 07/03/2018] [Indexed: 12/19/2022] Open
Abstract
Background: Microsatellite and chromosomal instability have been investigated in Hodgkin lymphoma (HL). Materials and Methods: We studied seven HL cell lines (five Nodular Sclerosis (NS) and two Mixed Cellularity (MC)) and patient peripheral blood lymphocytes (100 NS-HL and 23 MC-HL). Microsatellite instability (MSI) was assessed by PCR. Chromosomal instability and telomere dysfunction were investigated by FISH. DNA repair mechanisms were studied by transcriptomic and molecular approaches. Results: In the cell lines, we observed high MSI in L428 (4/5), KMH2, and HDLM2 (3/5), low MSI in L540, L591, and SUP-HD1, and none in L1236. NS-HL cell lines showed telomere shortening, associated with alterations of nuclear shape. Small cells were characterized by telomere loss and deletion, leading to chromosomal fusion, large nucleoplasmic bridges, and breakage/fusion/bridge (B/F/B) cycles, leading to chromosomal instability. The MC-HL cell lines showed substantial heterogeneity of telomere length. Intrachromosmal double strand breaks induced dicentric chromosome formation, high levels of micronucleus formation, and small nucleoplasmic bridges. B/F/B cycles induced complex chromosomal rearrangements. We observed a similar pattern in circulating lymphocytes of NS-HL and MC-HL patients. Transcriptome analysis confirmed the differences in the DNA repair pathways between the NS and MC cell lines. In addition, the NS-HL cell lines were radiosensitive and the MC-cell lines resistant to apoptosis after radiation exposure. Conclusions: In mononuclear NS-HL cells, loss of telomere integrity may present the first step in the ongoing process of chromosomal instability. Here, we identified, MSI as an additional mechanism for genomic instability in HL.
Collapse
|
10
|
Abstract
This review by Levine and Holland reviews the sources of mitotic errors in human tumors and their effect on cell fitness and transformation. They discuss new findings that suggest that chromosome missegregation can produce a proinflammatory environment and impact tumor responsiveness to immunotherapy and survey the vulnerabilities exposed by cell division errors and how they can be exploited therapeutically. Mitosis is a delicate event that must be executed with high fidelity to ensure genomic stability. Recent work has provided insight into how mitotic errors shape cancer genomes by driving both numerical and structural alterations in chromosomes that contribute to tumor initiation and progression. Here, we review the sources of mitotic errors in human tumors and their effect on cell fitness and transformation. We discuss new findings that suggest that chromosome missegregation can produce a proinflammatory environment and impact tumor responsiveness to immunotherapy. Finally, we survey the vulnerabilities exposed by cell division errors and how they can be exploited therapeutically.
Collapse
Affiliation(s)
- Michelle S Levine
- Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
| | - Andrew J Holland
- Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
| |
Collapse
|
11
|
Cuceu C, Hempel WM, Sabatier L, Bosq J, Carde P, M'kacher R. Chromosomal Instability in Hodgkin Lymphoma: An In-Depth Review and Perspectives. Cancers (Basel) 2018; 10:cancers10040091. [PMID: 29587466 PMCID: PMC5923346 DOI: 10.3390/cancers10040091] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2018] [Revised: 03/20/2018] [Accepted: 03/23/2018] [Indexed: 12/22/2022] Open
Abstract
The study of Hodgkin lymphoma (HL), with its unique microenvironment and long-term follow-up, has provided exceptional insights into several areas of tumor biology. Findings in HL have not only improved our understanding of human carcinogenesis, but have also pioneered its translation into the clinics. HL is a successful paradigm of modern treatment strategies. Nonetheless, approximately 15–20% of patients with advanced stage HL still die following relapse or progressive disease and a similar proportion of patients are over-treated, leading to treatment-related late sequelae, including solid tumors and organ dysfunction. The malignant cells in HL are characterized by a highly altered genomic landscape with a wide spectrum of genomic alterations, including somatic mutations, copy number alterations, complex chromosomal rearrangements, and aneuploidy. Here, we review the chromosomal instability mechanisms in HL, starting with the cellular origin of neoplastic cells and the mechanisms supporting HL pathogenesis, focusing particularly on the role of the microenvironment, including the influence of viruses and macrophages on the induction of chromosomal instability in HL. We discuss the emerging possibilities to exploit these aberrations as prognostic biomarkers and guides for personalized patient management.
Collapse
Affiliation(s)
- Corina Cuceu
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, 91534 Paris-Saclay, France.
| | - William M Hempel
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, 91534 Paris-Saclay, France.
| | - Laure Sabatier
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, 91534 Paris-Saclay, France.
| | - Jacques Bosq
- Departement of Anapathology, Gustave Roussy Cancer Campus, 94805 Villejuif, France.
| | - Patrice Carde
- Department of Hematology Gustave Roussy Cancer Campus, 94800 Villejuif, France.
| | - Radhia M'kacher
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, 91534 Paris-Saclay, France.
- Cell Environment, DNA damages R&D, Oncology section, 75020 Paris, France.
| |
Collapse
|
12
|
Frenzel M, Ricoul M, Benadjaoud MA, Bellamy M, Lenain A, Haddy N, Diallo I, Mateus C, de Vathaire F, Sabatier L. Retrospective cohort study and biobanking of patients treated for hemangioma in childhood – telomeres as biomarker of aging and radiation exposure. Int J Radiat Biol 2017. [DOI: 10.1080/09553002.2017.1337278] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Monika Frenzel
- PROCyTOX (Radiation Oncology, Cytogenetics, and Toxicology Platform), DRF Commissariat à l’Energie Atomique et aux Energies Alternatives CEA, Paris, Saclay, France
| | - Michelle Ricoul
- PROCyTOX (Radiation Oncology, Cytogenetics, and Toxicology Platform), DRF Commissariat à l’Energie Atomique et aux Energies Alternatives CEA, Paris, Saclay, France
| | | | - Marion Bellamy
- PROCyTOX (Radiation Oncology, Cytogenetics, and Toxicology Platform), DRF Commissariat à l’Energie Atomique et aux Energies Alternatives CEA, Paris, Saclay, France
- Radiation Epidemiology Group, INSERM U1018, Villejuif, Université Paris, Saclay, France
| | - Aude Lenain
- PROCyTOX (Radiation Oncology, Cytogenetics, and Toxicology Platform), DRF Commissariat à l’Energie Atomique et aux Energies Alternatives CEA, Paris, Saclay, France
| | - Nadia Haddy
- Radiation Epidemiology Group, INSERM U1018, Villejuif, Université Paris, Saclay, France
| | - Ibrahima Diallo
- Radiation Epidemiology Group, INSERM U1018, Villejuif, Université Paris, Saclay, France
| | - Christine Mateus
- Service de dermatologie, Gustave Roussy, Université Paris-Saclay, Département de Médecine Oncologique, Villejuif, France
| | - Florent de Vathaire
- Radiation Epidemiology Group, INSERM U1018, Villejuif, Université Paris, Saclay, France
| | - Laure Sabatier
- PROCyTOX (Radiation Oncology, Cytogenetics, and Toxicology Platform), DRF Commissariat à l’Energie Atomique et aux Energies Alternatives CEA, Paris, Saclay, France
| |
Collapse
|
13
|
Kaddour A, Colicchio B, Buron D, El Maalouf E, Laplagne E, Borie C, Ricoul M, Lenain A, Hempel WM, Morat L, Al Jawhari M, Cuceu C, Heidingsfelder L, Jeandidier E, Deschênes G, Dieterlen A, El May M, Girinsky T, Bennaceur-Griscelli A, Carde P, Sabatier L, M'kacher R. Transmission of Induced Chromosomal Aberrations through Successive Mitotic Divisions in Human Lymphocytes after In Vitro and In Vivo Radiation. Sci Rep 2017; 7:3291. [PMID: 28607452 PMCID: PMC5468351 DOI: 10.1038/s41598-017-03198-7] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Accepted: 04/24/2017] [Indexed: 11/10/2022] Open
Abstract
The mechanisms behind the transmission of chromosomal aberrations (CA) remain unclear, despite a large body of work and major technological advances in chromosome identification. We reevaluated the transmission of CA to second- and third-division cells by telomere and centromere (TC) staining followed by M-FISH. We scored CA in lymphocytes of healthy donors after in vitro irradiation and those of cancer patients treated by radiation therapy more than 12 years before. Our data demonstrate, for the first time, that dicentric chromosomes (DCs) decreased by approximately 50% per division. DCs with two centromeres in close proximity were more efficiently transmitted, representing 70% of persistent DCs in ≥M3 cells. Only 1/3 of acentric chromosomes (ACs), ACs with four telomeres, and interstitial ACs, were paired in M2 cells and associated with specific DCs configurations. In lymphocytes of cancer patients, 82% of detected DCs were characterized by these specific configurations. Our findings demonstrate the high stability of DCs with two centromeres in close proximity during cell division. The frequency of telomere deletion increased during cell cycle progression playing an important role in chromosomal instability. These findings could be exploited in the follow-up of exposed populations.
Collapse
Affiliation(s)
- Akram Kaddour
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France.,Tunis El Manar University, School of Medicine, Tunis, Tunisia
| | - Bruno Colicchio
- Laboratoire MIPS Groupe IMTI Université de Haute-Alsace, Mulhouse, France
| | - Diane Buron
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Elie El Maalouf
- Laboratoire MIPS Groupe IMTI Université de Haute-Alsace, Mulhouse, France
| | | | - Claire Borie
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, Villejuif, France
| | - Michelle Ricoul
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Aude Lenain
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - William M Hempel
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Luc Morat
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Mustafa Al Jawhari
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Corina Cuceu
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | | | - Eric Jeandidier
- Service de Génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, 68070, Mulhouse, France
| | | | - Alain Dieterlen
- Laboratoire MIPS Groupe IMTI Université de Haute-Alsace, Mulhouse, France
| | - Michèle El May
- Tunis El Manar University, School of Medicine, Tunis, Tunisia
| | - Theodore Girinsky
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
| | | | - Patrice Carde
- Department of Hematology, Gustave Roussy cancer Campus, Villejuif, France
| | - Laure Sabatier
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Radhia M'kacher
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France. .,Cell Environment, Paris, France.
| |
Collapse
|
14
|
Finot F, Kaddour A, Morat L, Mouche I, Zaguia N, Cuceu C, Souverville D, Négrault S, Cariou O, Essahli A, Prigent N, Saul J, Paillard F, Heidingsfelder L, Lafouge P, Al Jawhari M, Hempel WM, El May M, Colicchio B, Dieterlen A, Jeandidier E, Sabatier L, Clements J, M'Kacher R. Genotoxic risk of ethyl-paraben could be related to telomere shortening. J Appl Toxicol 2016; 37:758-771. [DOI: 10.1002/jat.3425] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2016] [Revised: 11/01/2016] [Accepted: 11/01/2016] [Indexed: 01/22/2023]
Affiliation(s)
- F. Finot
- Covance Laboratory; 78440 Porcheville France
- Cell Environment; Paris France
| | - A. Kaddour
- Cell Environment; Paris France
- Tunis El Manar University; School of Medicine; Tunis Tunisia
| | - L. Morat
- Radiology and Oncology Laboratory, IRCM, DSV; Commissariat à l'energie atomique (CEA); Fontenay-aux Roses France
| | - I. Mouche
- Covance Laboratory; 78440 Porcheville France
- Cell Environment; Paris France
| | - N. Zaguia
- Radiology and Oncology Laboratory, IRCM, DSV; Commissariat à l'energie atomique (CEA); Fontenay-aux Roses France
| | - C. Cuceu
- Radiology and Oncology Laboratory, IRCM, DSV; Commissariat à l'energie atomique (CEA); Fontenay-aux Roses France
| | | | - S. Négrault
- Covance Laboratory; 78440 Porcheville France
| | - O. Cariou
- Covance Laboratory; 78440 Porcheville France
| | - A. Essahli
- Covance Laboratory; 78440 Porcheville France
| | - N. Prigent
- Covance Laboratory; 78440 Porcheville France
| | - J. Saul
- Covance Laboratories; Yorkshire HG3 1PY UK
| | - F. Paillard
- Covance Laboratory; 78440 Porcheville France
| | | | - P. Lafouge
- Covance Laboratory; 78440 Porcheville France
| | | | - W. M. Hempel
- Radiology and Oncology Laboratory, IRCM, DSV; Commissariat à l'energie atomique (CEA); Fontenay-aux Roses France
| | - M. El May
- Tunis El Manar University; School of Medicine; Tunis Tunisia
| | - B. Colicchio
- Laboratoire MIPS - Groupe IMTI Université de Haute-Alsace; F-68093 Mulhouse France
| | - A. Dieterlen
- Laboratoire MIPS - Groupe IMTI Université de Haute-Alsace; F-68093 Mulhouse France
| | - E. Jeandidier
- Service de génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace; 68070 Mulhouse France
| | - L. Sabatier
- Radiology and Oncology Laboratory, IRCM, DSV; Commissariat à l'energie atomique (CEA); Fontenay-aux Roses France
| | | | - R. M'Kacher
- Cell Environment; Paris France
- Radiology and Oncology Laboratory, IRCM, DSV; Commissariat à l'energie atomique (CEA); Fontenay-aux Roses France
| |
Collapse
|
15
|
Ainsbury E, Badie C, Barnard S, Manning G, Moquet J, Abend M, Antunes AC, Barrios L, Bassinet C, Beinke C, Bortolin E, Bossin L, Bricknell C, Brzoska K, Buraczewska I, Castaño CH, Čemusová Z, Christiansson M, Cordero SM, Cosler G, Monaca SD, Desangles F, Discher M, Dominguez I, Doucha-Senf S, Eakins J, Fattibene P, Filippi S, Frenzel M, Georgieva D, Gregoire E, Guogyte K, Hadjidekova V, Hadjiiska L, Hristova R, Karakosta M, Kis E, Kriehuber R, Lee J, Lloyd D, Lumniczky K, Lyng F, Macaeva E, Majewski M, Vanda Martins S, McKeever SW, Meade A, Medipally D, Meschini R, M’kacher R, Gil OM, Montero A, Moreno M, Noditi M, Oestreicher U, Oskamp D, Palitti F, Palma V, Pantelias G, Pateux J, Patrono C, Pepe G, Port M, Prieto MJ, Quattrini MC, Quintens R, Ricoul M, Roy L, Sabatier L, Sebastià N, Sholom S, Sommer S, Staynova A, Strunz S, Terzoudi G, Testa A, Trompier F, Valente M, Hoey OV, Veronese I, Wojcik A, Woda C. Integration of new biological and physical retrospective dosimetry methods into EU emergency response plans – joint RENEB and EURADOS inter-laboratory comparisons. Int J Radiat Biol 2016; 93:99-109. [DOI: 10.1080/09553002.2016.1206233] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Elizabeth Ainsbury
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Christophe Badie
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Stephen Barnard
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Grainne Manning
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Jayne Moquet
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Michael Abend
- Bundeswehr Institute of Radiobiology (BIR), Munich, Germany
| | - Ana Catarina Antunes
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico (IST/ITN), Universidade de Lisboa, Bobadela-LRS, Portugal
| | | | - Celine Bassinet
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Paris, France
| | - Christina Beinke
- Bundeswehr Institute of Radiobiology affiliated to the University of Ulm (UULM), Munich, Germany
| | | | - Lily Bossin
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
- Durham University (DUR), Durham, UK
| | - Clare Bricknell
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Kamil Brzoska
- Institute of Nuclear Chemistry and Technology (INCT), Warsaw, Poland
| | - Iwona Buraczewska
- Institute of Nuclear Chemistry and Technology (INCT), Warsaw, Poland
| | | | - Zina Čemusová
- Státní ústav radiační ochrany (SÚRO), Prague, Czech Republic
| | | | | | - Guillaume Cosler
- Institut de Recherche Biomédicale des Armées (IRBA), Paris, France
| | | | | | - Michael Discher
- Salzburg University Department of Geography and Geology, Salzburg, Austria
| | | | | | - Jon Eakins
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | | | | | - Monika Frenzel
- PROCyTOX, Commissariat à l’Energie Atomique et aux Energies Alternatives, Université Paris-Saclay (CEA), Fontenay-aux-Roses, France
| | - Dimka Georgieva
- National Center of Radiobiology and Radiation Protection (NCRRP), Bulgaria
| | - Eric Gregoire
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Paris, France
| | | | | | | | - Rositsa Hristova
- National Center of Radiobiology and Radiation Protection (NCRRP), Bulgaria
| | - Maria Karakosta
- Laboratory of Health Physics, Radiobiology & Cytogenetics Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety National Center for Scientific Research “Demokritos” (NCSRD), Greece
| | - Enikő Kis
- National Public Health Centre – National Research Institute for Radiobiology and Radiohygiene (NRIRR), Hungary
| | - Ralf Kriehuber
- Radiation Biology Unit Forschungszentrum Jülich GmbH (FzJ), Jülich, Germany
| | - Jungil Lee
- Korea Atomic Energy Research Institute (KAERI), Daejeon, South Korea
| | - David Lloyd
- Public Health England Centre for Radiation, Chemical and Environmental Hazards (PHE), Chilton, UK
| | - Katalin Lumniczky
- National Public Health Centre – National Research Institute for Radiobiology and Radiohygiene (NRIRR), Hungary
| | - Fiona Lyng
- Dublin Institute of Technology (DIT), Dublin, Ireland
| | - Ellina Macaeva
- Belgian Nuclear Research Centre (SCK-CEN), Mol, Belgium
- Ghent University (GU), Ghent, Belgium
| | | | - S. Vanda Martins
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico (IST/ITN), Universidade de Lisboa, Bobadela-LRS, Portugal
| | | | - Aidan Meade
- Dublin Institute of Technology (DIT), Dublin, Ireland
| | | | | | - Radhia M’kacher
- PROCyTOX, Commissariat à l’Energie Atomique et aux Energies Alternatives, Université Paris-Saclay (CEA), Fontenay-aux-Roses, France
| | - Octávia Monteiro Gil
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico (IST/ITN), Universidade de Lisboa, Bobadela-LRS, Portugal
| | - Alegria Montero
- Radiation Protection Service, IIS La Fe, Health Research Institute (LAFE), Spain
| | - Mercedes Moreno
- Laboratorio de Dosimetría Biológica, Servicio de Oncología Radioterápica, Hospital General Universitario Gregorio Marañón (SERMAS), Spain
| | | | - Ursula Oestreicher
- Bundesamt fuer Strahlenschutz (BfS), Department Radiation Protection and Health, Neuherberg, Germany
| | - Dominik Oskamp
- Radiation Biology Unit Forschungszentrum Jülich GmbH (FzJ), Jülich, Germany
| | | | - Valentina Palma
- Laboratory of Biosafety and Risk Assessment Division of Health Protection Technologies (ENEA) Casaccia Research Center, Italy
| | - Gabriel Pantelias
- Laboratory of Health Physics, Radiobiology & Cytogenetics Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety National Center for Scientific Research “Demokritos” (NCSRD), Greece
| | - Jerome Pateux
- Institut de Recherche Biomédicale des Armées (IRBA), Paris, France
| | - Clarice Patrono
- Laboratory of Biosafety and Risk Assessment Division of Health Protection Technologies (ENEA) Casaccia Research Center, Italy
| | - Gaetano Pepe
- Università degli Studi della Tuscia (UNITUS), Italy
| | - Matthias Port
- Bundeswehr Institute of Radiobiology (BIR), Munich, Germany
| | - María Jesús Prieto
- Laboratorio de Dosimetría Biológica, Servicio de Oncología Radioterápica, Hospital General Universitario Gregorio Marañón (SERMAS), Spain
| | | | - Roel Quintens
- Belgian Nuclear Research Centre (SCK-CEN), Mol, Belgium
| | - Michelle Ricoul
- PROCyTOX, Commissariat à l’Energie Atomique et aux Energies Alternatives, Université Paris-Saclay (CEA), Fontenay-aux-Roses, France
| | - Laurence Roy
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Paris, France
| | - Laure Sabatier
- PROCyTOX, Commissariat à l’Energie Atomique et aux Energies Alternatives, Université Paris-Saclay (CEA), Fontenay-aux-Roses, France
| | - Natividad Sebastià
- Radiation Protection Service, IIS La Fe, Health Research Institute (LAFE), Spain
| | | | - Sylwester Sommer
- Institute of Nuclear Chemistry and Technology (INCT), Warsaw, Poland
| | - Albena Staynova
- National Center of Radiobiology and Radiation Protection (NCRRP), Bulgaria
| | - Sonja Strunz
- Leibniz Institute for Farm Animal Biology (FBN), Dummerstorf, Germany
| | - Georgia Terzoudi
- Laboratory of Health Physics, Radiobiology & Cytogenetics Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety National Center for Scientific Research “Demokritos” (NCSRD), Greece
| | - Antonella Testa
- Laboratory of Biosafety and Risk Assessment Division of Health Protection Technologies (ENEA) Casaccia Research Center, Italy
| | - Francois Trompier
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Paris, France
| | - Marco Valente
- Institut de Recherche Biomédicale des Armées (IRBA), Paris, France
| | | | - Ivan Veronese
- Università degli Studi di Milano (UNIMI), Milano, Italy
| | | | - Clemens Woda
- Helmholtz Zentrum München (HMGU), Neuherberg, Germany
| |
Collapse
|
16
|
Jamal-Hanjani M, A'Hern R, Birkbak NJ, Gorman P, Grönroos E, Ngang S, Nicola P, Rahman L, Thanopoulou E, Kelly G, Ellis P, Barrett-Lee P, Johnston SRD, Bliss J, Roylance R, Swanton C. Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. Ann Oncol 2015; 26:1340-6. [PMID: 26003169 DOI: 10.1093/annonc/mdv178] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Accepted: 03/28/2015] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Chromosomal instability (CIN) has been shown to be associated with drug resistance and poor clinical outcome in several cancer types. However, in oestrogen receptor (ER)-negative breast cancer we have previously demonstrated that extreme CIN is associated with improved clinical outcome, consistent with a negative impact of CIN on tumour fitness and growth. The aim of this current study was to validate this finding using previously defined CIN thresholds in a much larger prospective cohort from a randomised, controlled, clinical trial. PATIENTS AND METHODS As a surrogate measurement of CIN, dual centromeric fluorescence in situ hybridisation was performed for both chromosomes 2 and 15 on 1173 tumours from the breast cancer TACT trial (CRUK01/001). Each tumour was scored manually and the mean percentage of cells deviating from the modal centromere number was used to define four CIN groups (MCD1-4), where tumours in the MCD4 group were defined as having extreme CIN. RESULTS In a multivariate analysis of disease-free survival, with a median follow-up of 91 months, increasing CIN was associated with improved outcome in patients with ER-negative cancer (P trend = 0.03). A similar pattern was seen in ER-negative/HER2-negative cancers (Ptrend = 0.007). CONCLUSIONS This prospective validation cohort study further substantiated the association between extreme CIN and improved outcome in ER-negative breast cancers. Identifying such patients with extreme CIN may help distinguish good from poor prognostic groups, and therefore support treatment and risk stratification in this aggressive breast cancer subtype.
Collapse
Affiliation(s)
- M Jamal-Hanjani
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London
| | - R A'Hern
- ICR-CTSU, Division of Clinical Studies, The Institute of Cancer Research, London
| | - N J Birkbak
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London The Francis Crick Institute, 44 Lincoln's Inn Fields, London
| | - P Gorman
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London
| | - E Grönroos
- The Francis Crick Institute, 44 Lincoln's Inn Fields, London
| | - S Ngang
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London
| | - P Nicola
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London
| | - L Rahman
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London
| | - E Thanopoulou
- The Francis Crick Institute, 44 Lincoln's Inn Fields, London
| | - G Kelly
- The Francis Crick Institute, 44 Lincoln's Inn Fields, London
| | - P Ellis
- Guy's and St Thomas' NHS Trust, London
| | | | | | - J Bliss
- ICR-CTSU, Division of Clinical Studies, The Institute of Cancer Research, London
| | - R Roylance
- Barts Cancer Institute, Queen Mary University of London, London, UK
| | - C Swanton
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London The Francis Crick Institute, 44 Lincoln's Inn Fields, London
| |
Collapse
|
17
|
How C, Bruce J, So J, Pintilie M, Haibe-Kains B, Hui A, Clarke BA, Hedley DW, Hill RP, Milosevic M, Fyles A, Liu FF. Chromosomal instability as a prognostic marker in cervical cancer. BMC Cancer 2015; 15:361. [PMID: 25944123 PMCID: PMC4433070 DOI: 10.1186/s12885-015-1372-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Accepted: 04/27/2015] [Indexed: 01/10/2023] Open
Abstract
Background Cervical cancer is the third most common cancer in women globally, and despite treatment, distant metastasis and nodal recurrence will still develop in approximately 30% of patients. The ability to predict which patients are likely to experience distant relapse would allow clinicians to better tailor treatment. Previous studies have investigated the role of chromosomal instability (CIN) in cancer, which can promote tumour initiation and growth; a hallmark of human malignancies. In this study, we sought to examine the published CIN70 gene signature in a cohort of cervical cancer patients treated at the Princess Margaret (PM) Cancer Centre and an independent cohort of The Cancer Genome Atlas (TCGA) cervical cancer patients, to determine if this CIN signature associated with patient outcome. Methods Cervical cancer samples were collected from 79 patients, treated between 2000–2007 at the PM, prior to undergoing curative chemo-radiation. Total RNA was extracted from each patient sample and analyzed using the GeneChip Human Genome U133 Plus 2.0 array (Affymetrix). Results High CIN70 scores were significantly related to increased chromosomal alterations in TCGA cervical cancer patients, including a higher percentage of genome altered and a higher number of copy number alterations. In addition, this same CIN70 signature was shown to be predictive of para-aortic nodal relapse in the PM Cancer Centre cohort. Conclusions These findings demonstrate that chromosomal instability plays an important role in cervical cancer, and is significantly associated with patient outcome. For the first time, this CIN70 gene signature provided prognostic value for patients with cervical cancer.
Collapse
Affiliation(s)
- Christine How
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
| | - Jeff Bruce
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
| | - Jonathan So
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. .,Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
| | - Melania Pintilie
- Division of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
| | - Benjamin Haibe-Kains
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. .,Medical Biophysics Department, University of Toronto, Toronto, ON, Canada.
| | - Angela Hui
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
| | - Blaise A Clarke
- Department of Pathology, University Health Network, Toronto, ON, Canada.
| | - David W Hedley
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. .,Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
| | - Richard P Hill
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
| | - Michael Milosevic
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. .,Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
| | - Anthony Fyles
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. .,Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
| | - Fei-Fei Liu
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. .,Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. .,Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
| |
Collapse
|
18
|
Comar M, Delbue S, Zanotta N, Valencic E, Piscianz E, Del Savio R, Tesser A, Tommasini A, Ferrante P. In vivo detection of polyomaviruses JCV and SV40 in mesenchymal stem cells from human umbilical cords. Pediatr Blood Cancer 2014; 61:1347-9. [PMID: 24623583 DOI: 10.1002/pbc.24943] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2013] [Accepted: 12/17/2013] [Indexed: 11/09/2022]
Abstract
BACKGROUND Multipotent stromal cells are present in the Wharton's jelly matrix (WJSC) of the umbilical cord and can be used as an allogeneic source of cells to treat immunological disorders. Recently it was demonstrated that adult bone marrow (BM)-derived mesenchimal stromal cells (MSC) are susceptible to infection with viruses showing potential oncogenic properties, such as the polyomavirus JC (JCV). The aim of this study was to investigate the presence of human polyomaviruses (JCV, BK Virus-BKV, SV40, and Merkel cell polyomavirus-MCPyV) in WJSC, and explore the risk of infection. PROCEDURE MSC samples from 35 umbilical cords were investigated by quantitative Real Time PCRs for the presence of DNA sequences of JCV, BKV, SV40, and MCPyV. RESULTS JCV DNA was detected in 1/35 (2.8%) of MSC samples, while SV40 DNA was found in 3/35 (8.6%) of the examined samples. None of the samples showed sequences of BKV and MCPyV. CONCLUSIONS The present study demonstrates the in vivo ability of polyomaviruses to infect WJSC. Since the therapeutic approach with the WJSC has high potentiality and a more intensive use can be easily hypothesized, the need to develop consensus guidelines to detect rare viral infections in MSC is pressing.
Collapse
Affiliation(s)
- Manola Comar
- Institute for Maternal and Child Health-IRCCS "Burlo Garofolo"-Trieste, Trieste, Italy; Medical Science Department, University of Trieste, Trieste, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Moens U, Van Ghelue M, Ehlers B. Are human polyomaviruses co-factors for cancers induced by other oncoviruses? Rev Med Virol 2014; 24:343-60. [PMID: 24888895 DOI: 10.1002/rmv.1798] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Revised: 04/25/2014] [Accepted: 05/07/2014] [Indexed: 12/16/2022]
Abstract
Presently, 12 human polyomaviruses are known: BK polyomavirus (BKPyV), JCPyV, KIPyV, WUPyV, Merkel cell polyomavirus (MCPyV), HPyV6, HPyV7, Trichodysplasia spinulosa-associated polyomavirus, HPyV9, HPyV10, STLPyV and HPyV12. In addition, the non-human primate polyomavirus simian virus 40 (SV40) seems to circulate in the human population. MCPyV was first described in 2008 and is now accepted to be an etiological factor in about 80% of the rare but aggressive skin cancer Merkel cell carcinoma. SV40, BKPyV and JCPyV or part of their genomes can transform cells, including human cells, and induce tumours in animal models. Moreover, DNA and RNA sequences and proteins of these three viruses have been discovered in tumour tissue. Despite these observations, their role in cancer remains controversial. So far, an association between cancer and the other human polyomaviruses is lacking. Because human polyomavirus DNA has been found in a broad spectrum of cell types, simultaneous dwelling with other oncogenic viruses is possible. Co-infecting human polyomaviruses may therefore act as a co-factor in the development of cancer, including those induced by other oncoviruses. Reviewing studies that report co-infection with human polyomaviruses and other tumour viruses in cancer tissue fail to detect a clear link between co-infection and cancer. Directions for future studies to elaborate on a possible auxiliary role of human polyomaviruses in cancer are suggested, and the mechanisms by which human polyomaviruses may synergize with other viruses in oncogenic transformation are discussed.
Collapse
Affiliation(s)
- Ugo Moens
- University of Tromsø, Faculty of Health Sciences, Institute of Medical Biology, Molecular Inflammation Research Group, Tromsø, Norway
| | | | | |
Collapse
|
20
|
Tseng CE, Yeh CM, Fang CY, Shay J, Chen PL, Lin MC, Chang D, Wang M. Detection of human JCPyV and BKPyV in diffuse large B-cell lymphoma of the GI tract. Eur J Clin Microbiol Infect Dis 2013. [PMID: 24258263 DOI: 10.1007/s10096-d13-2010-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Previous studies have demonstrated that infection with human polyomavirus, such as JCPyV and BKPyV, might be associated with various human tumors. However, an association between human JCPyV and BKPyV infection and diffuse large B-cell lymphoma (DLBCL) has not been reported. The purpose of this study was to examine DLBCLs of the gastrointestinal tract for evidence of human polyomavirus infection. Nested PCR and DNA sequencing were employed for viral DNA detection and viral genotype identification. In addition, two viral proteins, the large tumor antigen (LT) and the major structural protein (VP1), were detected by immunohistochemistry (IHC). Human JCPyV and BKPyV DNA was detected in 14 out of 16 tissue samples (87.5%), whereby nine cases were infected with JCPyV and five cases were infected with BKPyV. Both archetypal and rearranged genotypes of JCPyV and BKPyV were detected in the tissues. LT was detected in 11 tissue samples (68.75%). However, VP1 was not detected in any of the tissue samples. The presence of human JCPyV and BKPyV DNA and protein in DLBCL tissues of gastrointestinal tract were first reported in this study. The current results provide evidence of a possible association between human JCPyV and BKPyV infection and DLBCL.
Collapse
Affiliation(s)
- C E Tseng
- Department of Anatomic Pathology, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Tseng CE, Yeh CM, Fang CY, Shay J, Chen PL, Lin MC, Chang D, Wang M. Detection of human JCPyV and BKPyV in diffuse large B-cell lymphoma of the GI tract. Eur J Clin Microbiol Infect Dis 2013; 33:665-72. [PMID: 24258263 DOI: 10.1007/s10096-013-2010-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2013] [Accepted: 10/22/2013] [Indexed: 10/26/2022]
Abstract
Previous studies have demonstrated that infection with human polyomavirus, such as JCPyV and BKPyV, might be associated with various human tumors. However, an association between human JCPyV and BKPyV infection and diffuse large B-cell lymphoma (DLBCL) has not been reported. The purpose of this study was to examine DLBCLs of the gastrointestinal tract for evidence of human polyomavirus infection. Nested PCR and DNA sequencing were employed for viral DNA detection and viral genotype identification. In addition, two viral proteins, the large tumor antigen (LT) and the major structural protein (VP1), were detected by immunohistochemistry (IHC). Human JCPyV and BKPyV DNA was detected in 14 out of 16 tissue samples (87.5%), whereby nine cases were infected with JCPyV and five cases were infected with BKPyV. Both archetypal and rearranged genotypes of JCPyV and BKPyV were detected in the tissues. LT was detected in 11 tissue samples (68.75%). However, VP1 was not detected in any of the tissue samples. The presence of human JCPyV and BKPyV DNA and protein in DLBCL tissues of gastrointestinal tract were first reported in this study. The current results provide evidence of a possible association between human JCPyV and BKPyV infection and DLBCL.
Collapse
Affiliation(s)
- C E Tseng
- Department of Anatomic Pathology, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Mitchell G, Fereday S, DeFazio A, Bowtell DDL, Kristensen GB, Lingjærde OC, Børresen-Dale AL. High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One 2013; 8:e54356. [PMID: 23372714 PMCID: PMC3553118 DOI: 10.1371/journal.pone.0054356] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2012] [Accepted: 12/11/2012] [Indexed: 01/31/2023] Open
Abstract
Genomic instability and copy number alterations in cancer are generally associated with poor prognosis; however, recent studies have suggested that extreme levels of genomic aberrations may be beneficial for the survival outcome for patients with specific tumour types. We investigated the extent of genomic instability in predominantly high-grade serous ovarian cancers (SOC) using two independent datasets, generated in Norway (n = 74) and Australia (n = 70), respectively. Genomic instability was quantified by the Total Aberration Index (TAI), a measure of the abundance and genomic size of copy number changes in a tumour. In the Norwegian cohort, patients with TAI above the median revealed significantly prolonged overall survival (p<0.001) and progression-free survival (p<0.05). In the Australian cohort, patients with above median TAI showed prolonged overall survival (p<0.05) and moderately, but not significantly, prolonged progression-free survival. Results were confirmed by univariate and multivariate Cox regression analyses with TAI as a continuous variable. Our results provide further evidence supporting an association between high level of genomic instability and prolonged survival of high-grade SOC patients, possibly as disturbed genome integrity may lead to increased sensitivity to chemotherapeutic agents.
Collapse
Affiliation(s)
- Lars O Baumbusch
- Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 2012; 25:471-506. [PMID: 22763635 DOI: 10.1128/cmr.05031-11] [Citation(s) in RCA: 289] [Impact Index Per Article: 24.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Progressive multifocal leukoencephalopathy (PML) is a debilitating and frequently fatal central nervous system (CNS) demyelinating disease caused by JC virus (JCV), for which there is currently no effective treatment. Lytic infection of oligodendrocytes in the brain leads to their eventual destruction and progressive demyelination, resulting in multiple foci of lesions in the white matter of the brain. Before the mid-1980s, PML was a relatively rare disease, reported to occur primarily in those with underlying neoplastic conditions affecting immune function and, more rarely, in allograft recipients receiving immunosuppressive drugs. However, with the onset of the AIDS pandemic, the incidence of PML has increased dramatically. Approximately 3 to 5% of HIV-infected individuals will develop PML, which is classified as an AIDS-defining illness. In addition, the recent advent of humanized monoclonal antibody therapy for the treatment of autoimmune inflammatory diseases such as multiple sclerosis (MS) and Crohn's disease has also led to an increased risk of PML as a side effect of immunotherapy. Thus, the study of JCV and the elucidation of the underlying causes of PML are important and active areas of research that may lead to new insights into immune function and host antiviral defense, as well as to potential new therapies.
Collapse
|
24
|
Gu W, Fang FF, Li B, Cheng BB, Ling CQ. Characterization and Resistance Mechanisms of A 5-fluorouracil-resistant Hepatocellular Carcinoma Cell Line. Asian Pac J Cancer Prev 2012; 13:4807-14. [DOI: 10.7314/apjcp.2012.13.9.4807] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
25
|
Bakhoum SF, Danilova OV, Kaur P, Levy NB, Compton DA. Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2012; 17:7704-11. [PMID: 22184286 DOI: 10.1158/1078-0432.ccr-11-2049] [Citation(s) in RCA: 90] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
PURPOSE The specific role of chromosomal instability (CIN) in tumorigenesis has been a matter of conjecture. In part, this is due to the challenge of directly observing chromosome mis-segregation events as well as the inability to distinguish the role of CIN, which consists of increased rates of chromosome mis-segregation, from that of aneuploidy, which is a state of nondiploid chromosome number. EXPERIMENTAL DESIGN Here, we examine the contribution of CIN to the prognosis of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) by directly surveying tumor cells, fixed while undergoing anaphase, for evidence of chromosome mis-segregation. Hematoxylin and eosin-stained samples from a cohort of 54 patients were used to examine the relationship between frequencies of chromosome mis-segregation and patient prognosis, overall survival, and response to treatment. RESULTS We show that a two-fold increase in the frequency of chromosome mis-segregation led to a 24% decrease in overall survival and 48% decrease in relapse-free survival after treatment. The HR of death in patients with increased chromosome mis-segregation was 2.31 and these patients were more likely to present with higher tumor stage, exhibit tumor bone marrow involvement, and receive a higher International Prognostic Index score. CONCLUSIONS Increased rates of chromosome mis-segregation in DLBCL substantiate inferior outcome and poor prognosis. This is likely due to increased heterogeneity of tumor cells leading to a larger predilection for adaptation in response to external pressures such as metastasis and drug treatments. We propose that targeting CIN would yield superior prognosis and improved response to chemotherapeutic drugs.
Collapse
Affiliation(s)
- Samuel F Bakhoum
- Department of Biochemistry; The Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH 03755, USA.
| | | | | | | | | |
Collapse
|
26
|
Salas C, Niembro A, Lozano V, Gallardo E, Molina B, Sánchez S, Ramos S, Carnevale A, Pérez-Vera P, Rivera Luna R, Frias S. Persistent genomic instability in peripheral blood lymphocytes from Hodgkin lymphoma survivors. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2012; 53:271-280. [PMID: 22434555 DOI: 10.1002/em.21691] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/31/2011] [Revised: 02/21/2012] [Accepted: 02/21/2012] [Indexed: 05/31/2023]
Abstract
Advances in cancer treatment have led to an increase in patient survival. However, exposure to genotoxic chemotherapeutic agents and ionizing radiation may induce persistent genetic damage in cancer survivors. In this study, we detected genomic instability in chromosomes of peripheral blood lymphocytes from Hodgkin lymphoma patients, 2-17 years after MOPP (nitrogen mustard, Oncovin, procarbazine, and prednisone) chemotherapy with or without radiotherapy. Samples were obtained from 11 healthy individuals, 5 pretreatment patients, and 20 posttreatment patients. Cytogenetic analysis with GTG banding was performed on 1,000 lymphocyte metaphases per donor to identify genomic instability, including numerical and structural chromosomal aberrations, at a resolution of 10 Mb across the entire genome. Our results showed that anticancer treatment did not induce significant differences in the frequency of aneuploidy among the three study groups. However, 1 of the 11 healthy individuals, and 13 of the 20 posttreatment patients had a high frequency of chromosomal breaks and gross chromosomal rearrangements. The types of aberrations observed were random and complex, consistent with persistent genomic instability that was induced by cancer treatment. Clonal expansion of cells with chromosomal lesions was observed in one posttreatment patient only. These findings show that anticancer treatments induce persistent genomic instability, but not aneuploidy. Chemotherapy may affect genes with a role in DNA damage surveillance or repair, which in turn allows the accumulation of nontargeted structural chromosomal damage in future generations of cells. This genomic instability may facilitate the development of second malignancies in Hodgkin lymphoma survivors.
Collapse
Affiliation(s)
- C Salas
- Laboratorio de Cultivo de Tejidos, Departamento de Investigación en Genética Humana, Instituto Nacional de Pediatría, México
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Bakhoum SF, Compton DA. Chromosomal instability and cancer: a complex relationship with therapeutic potential. J Clin Invest 2012; 122:1138-43. [PMID: 22466654 PMCID: PMC3314464 DOI: 10.1172/jci59954] [Citation(s) in RCA: 196] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Chromosomal instability (CIN) is a hallmark of human neoplasms. Despite its widespread prevalence, knowledge of the mechanisms and contributions of CIN in cancer has been elusive. It is now evident that the role of CIN in tumor initiation and growth is more complex than previously thought. Furthermore, distinguishing CIN, which consists of elevated rates of chromosome missegregation, from aneuploidy, which is a state of abnormal chromosome number, is crucial to understanding their respective contributions in cancer. Collectively, experimental evidence suggests that CIN enables tumor adaptation by allowing tumors to constantly sample the aneuploid fitness landscape. This complex relationship, together with the potential to pharmacologically influence chromosome missegregation frequencies in cancer cells, offers previously unrecognized means to limit tumor growth and its response to therapy.
Collapse
Affiliation(s)
- Samuel F Bakhoum
- Department of Biochemistry and Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.
| | | |
Collapse
|